Group 1: Financial Performance - The company achieved a revenue of 471.51 million yuan in 2024, representing an 18.63% increase compared to the previous year [2] - The sales growth for the main business segments was 16.74% for raw materials, 35.51% for intermediates, and 45.82% for formulations [2] - The cash balance at the end of the reporting period was 1.03 billion yuan, indicating sufficient cash flow [4] Group 2: Strategic Initiatives - The company plans to extend its industrial chain by enhancing R&D innovation and product quality, aiming for a full industrial chain layout from raw materials to formulations [3] - The new investment project has been changed to a "300 tons/year A-40 (Atorvastatin Calcium) specialty raw material project," with a total investment of 414.39 million yuan, expected to be operational by December 31, 2027 [4] - R&D investment increased by 47.44% in 2024, with a focus on developing 17 ongoing projects related to antiviral, antidepressant, lipid-lowering, anti-inflammatory, anti-rheumatic, and anti-ulcer medications [8] Group 3: Market Expansion - The company has a significant portion of revenue from international markets, with major export regions including Asia, Europe, and America [3] - In 2024, overseas revenue accounted for 50% of total revenue, with a small proportion coming from direct exports to the U.S. [7] - The company is actively working to expand its market presence in the U.S. and other regions, despite limited impact from U.S. tariff policies [8] Group 4: Corporate Governance and Investor Relations - The company emphasizes shareholder returns and plans to maintain a sustainable dividend policy based on operational performance and cash flow [4] - Measures are in place to protect the rights of minority investors, including transparent voting processes and communication channels [6] - The company has established a robust internal control system to ensure compliance with revenue recognition standards [9]
海森药业(001367) - 投资者关系活动记录表（2024年度网上业绩说明会）